Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents.
Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents. The patenthad been challenged by Behringwerke AG of Germany, which did notappeal the patent office's decision denying its request, accordingto Immunomedics. The company's stock jumped 24% after the patentnews was announced.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.